SCHEMBL24620280

SCHEMBL24620280

O=C1NCc2cccc(Nc3nc(Nc4ccc(N5CCC(N6CCNCC6)CC5)cc4OC(F)F)ncc3Cl)c21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 6/20 0.60
▸ MAPK3 P27361 2/20 0.58
▸ ALK Q9UM73 15/20 0.57
▸ INSR P06213 10/20 0.55
▸ IGF1R P08069 9/20 0.55
▸ FGFR1 P11362 3/20 0.54
▸ FGFR2 P21802 3/20 0.54
▸ FGFR4 P22455 3/20 0.54
▸ FGFR3 P22607 3/20 0.54
▸ CHEK1 O14757 2/20 0.52
▸ AURKA O14965 2/20 0.52
▸ NUAK1 O60285 2/20 0.52
▸ JAK2 O60674 2/20 0.52
▸ STK10 O94804 2/20 0.52
▸ PRKD3 O94806 2/20 0.52
▸ CHEK2 O96017 2/20 0.52
▸ ABL1 P00519 2/20 0.52
▸ ERBB2 P04626 2/20 0.52
▸ LCK P06239 2/20 0.52
▸ FYN P06241 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30833035 1.00 EGFR (0.60) EGFRMAPK3ALKINSRIGF1R
SCHEMBL24620619 0.93 ALK (0.64) EGFRMAPK3ALKINSRIGF1R
SCHEMBL29791360 0.93 ALK (0.64) EGFRMAPK3ALKINSRIGF1R
SCHEMBL30833043 0.93 MAPK3 (0.66) EGFRMAPK3ALK
SCHEMBL24620313 0.93 MAPK3 (0.66) EGFRMAPK3ALK
SCHEMBL24620475 0.92 ALK (0.55) EGFRMAPK3ALKPLK1ULK1
SCHEMBL30833045 0.92 ALK (0.58) EGFRMAPK3ALKINSRIGF1R
SCHEMBL24620208 0.92 ALK (0.58) EGFRMAPK3ALKINSRIGF1R
SCHEMBL29791454 0.92 ALK (0.55) EGFRMAPK3ALKPLK1ULK1
SCHEMBL24620234 0.91 ALK (0.56) EGFRMAPK3ALKINSRIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022147622-A1 ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-07-14 — — WO disclosed
Send feedback